share_log

HC Wainwright & Co. Initiates Coverage On Moleculin Biotech With Buy Rating, Announces Price Target of $3

HC Wainwright & Co. Initiates Coverage On Moleculin Biotech With Buy Rating, Announces Price Target of $3

HC Wainwright & Co.以買入評級啓動對Moleculin Biotech的報道,宣佈目標股價爲3美元
Benzinga ·  2023/12/14 06:06

HC Wainwright & Co. analyst Vernon Bernardino initiates coverage on Moleculin Biotech (NASDAQ:MBRX) with a Buy rating and announces Price Target of $3.

HC Wainwright & Co. 分析師弗農·貝納迪諾開始對Moleculin Biotech(納斯達克股票代碼:MBRX)進行報道,評級爲買入,並宣佈目標股價爲3美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論